Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Minority Interest: 2010-2024

Historic Minority Interest for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to -$1.4 million.

  • Lineage Cell Therapeutics' Minority Interest rose 10.63% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 10.63%. This contributed to the annual value of -$1.4 million for FY2024, which is 1.93% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Minority Interest stood at -$1.4 million for FY2024, which was up 1.93% from -$1.4 million recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Minority Interest peaked at -$1.1 million during FY2020, and registered a low of -$1.4 million during FY2022.
  • For the 3-year period, Lineage Cell Therapeutics' Minority Interest averaged around -$1.4 million, with its median value being -$1.4 million (2023).
  • In the last 5 years, Lineage Cell Therapeutics' Minority Interest surged by 37.38% in 2020 and then declined by 23.41% in 2021.
  • Lineage Cell Therapeutics' Minority Interest (Yearly) stood at -$1.1 million in 2020, then decreased by 23.41% to -$1.3 million in 2021, then declined by 6.05% to -$1.4 million in 2022, then increased by 0.50% to -$1.4 million in 2023, then grew by 1.93% to -$1.4 million in 2024.